Results For "Semaphorin-3A"

1 News Found

Bayer advances fight against rare kidney disease with new experimental drug

R&D | December 07, 2025

Bayer advances fight against rare kidney disease with new experimental drug

Alport Syndrome is caused by genetic mutations affecting type IV collagen in the kidneys, ears, and eyes

Latest Stories

Takeda seals $1.2 billion oncology deal with Innovent Biologics

Bayer advances fight against rare kidney disease with new experimental drug

Denali clinches $275 million royalty deal to power potential breakthrough Hunter Syndrome therapy

White Papers

Chasing Consistency: Centralizing operations data is the key to optimizing chemicals plants

Implementing a digital transformation in chemical operations to maximize profitability

The complexity of compliance

The Sprint to the Summit: Unlocking Lab Efficiency through Digital Transformation

The guiding role of fluidized and spouted bed technologies in particle building processes

Interviews

Companies must shift from L1 costing to Life Cycle Cost Analysis: Abhilash Pasham, Associate GM - Central Engineering & Projects, Dr. Reddy's Laboratories

Companies must shift from L1 costing to Life Cycle Cost Analysis: Abhilash Pasham, Associate GM - Central Engineering & Projects, Dr. Reddy's Laboratories

Future of manufacturing lies in mobility based manufacturing: Sandeep Rathi, Founder & CEO, Sierra Instrumentation & Controls

Future of manufacturing lies in mobility based manufacturing: Sandeep Rathi, Founder & CEO, Sierra Instrumentation & Controls

Indian companies must make their own intermediates and support small industries: Dr. K. Nagaiah, Chief Scientist, CSIR - IICT, Hyderabad

Indian companies must make their own intermediates and support small industries: Dr. K. Nagaiah, Chief Scientist, CSIR - IICT, Hyderabad

Packaging